Last updated: January 15, 2025
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting
Phase
1
Condition
Obesity
Diabetes Prevention
Treatment
Placebo
Pioglitazone
Deferred weight loss
Clinical Study ID
NCT03866408
17-009837
2R01DK040484-30
Ages 18-55 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Men and Women between the ages of 18 and 55.
Women will be premenopausal
Non obese adults BMI between 18-25
Obese BMI 30-38
Exclusion Criteria, Pioglitazone package insert of contraindications for use:
Initiation in patients with established New York Heart Associations (NYHA) class III or IV Heart failure.
Use in patients with known hypersensitivity to pioglitazone or any other component of ACTOSE.
Study Design
Total Participants: 64
Treatment Group(s): 4
Primary Treatment: Placebo
Phase: 1
Study Start date:
November 12, 2018
Estimated Completion Date:
December 31, 2025
Study Description
Connect with a study center
Mayo Clinic in Rochester
Rochester, Minnesota 55905
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.